Disease modifying antirheumatic drugs: Longterm safety issues

Journal of Rheumatology

Volumn 28, Issue SUPPL. 62, 2001, Pages 10-15

  Capell, H A ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

DMARD; Hydroxychloroquine; Methotrexate; Rheumatoid arthritis; Sulfasalazine

Indexed keywords

ANTIRHEUMATIC AGENT; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; HYDROXYCHLOROQUINE; METHOTREXATE; SALAZOSULFAPYRIDINE;

CONFERENCE PAPER; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; REVIEW; SAFETY; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; HYDROXYCHLOROQUINE; METHOTREXATE; SAFETY; SULFASALAZINE; TREATMENT OUTCOME;

EID: 0034991081     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. Survival, prognosis and causes of death in rheumatoid arthritis
2. The mortality of rheumatoid arthritis
3. Total lymphoid irradiation in rheumatoid arthritis
4. Low-dose corticosteroid therapy in rheumatoid arthritis: Balancing the evidence
5. The risk of treatment. A study of RA patients attitudes
6. Methotrexate in rheumatoid arthritis: An update with focus on mechanisms involved in toxicity
7. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine
8. Efficacy and safety of leflunomide compared with placebo and sulfasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
9. Function and health-related quality of life. Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis
10. A long-term five year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis
11. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis
12. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis
13. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis
14. The relative toxicity of disease-modifying antirheumatic drugs
15. Aggressive treatment in early rheumatoid arthritis: A randomised controlled trial
16. Retinal toxicity in long term hydroxychloroquine treatment
17. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice
18. Sulfasalazine has a better efficacy/toxicity profile than auranofin - Evidence from a 5 year prospective, randomized trial
19. Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after random allocation to either sulfasalazine or penicillamine
20. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus
21. Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years
22. Response to sulfasalazine in rheumatoid arthritis: Life table analysis of a 5 year followup
23. Immunodeficiencies associated with sulphasalazine therapy in inflammatory arthritis
24. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts
25. Longterm prospective study of methotrexate in rheumatoid arthritis: Conclusion after 132 months of therapy
26. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis
27. Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients
28. Infections during low-dose methotrexate treatment in rheumatoid arthritis
29. The incidence of cancer associated with the treatment of rheumatoid arthritis
30. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis
31. Methotrexate effects in patient with rheumatoid arthritis with cardiovascular comorbidity
32. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis
33. Rheumatoid arthritis: Workload and outcome over 10 years
34. Utility of disease modifying antirheumatic drugs in sawtooth strategy. A prospective study of early rheumatoid arthritis patients up to 15 years
35. Outcome in patients with early rheumatoid arthritis treated according to the sawtooth strategy
36. Longterm mortality outcome in patients with rheumatoid arthritis: Early presenters continue to do well
37. Intramuscular gold therapy is associated with long survival in patients with rheumatoid arthritis
38. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis
39. Death attributed to antirheumatic medication in a nationwide series of 1666 patients with rheumatoid arthritis who have died
40. The efficacy and toxicity of combination therapy in rheumatoid arthritis
41. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications
42. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial
43. Longterm safety monitoring in rheumatoid arthritis. A proposal from OMERACT
44. A proposal for developing a large patient population cohort for longterm safety monitoring in rheumatoid arthritis
45. Effect of social deprivation on disease severity and outcome in patients with rheumatoid arthritis